Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7249810 | 0.99 | HCRTR2 (0.41) | HCRTR2CTSVCTSLMAOBMEN1 | |
| SCHEMBL7245117 | 0.91 | F10 (0.39) | CTSVCTSLMEN1KMT2ABCHE | |
| SCHEMBL7244715 | 0.87 | HCRTR2 (0.40) | HCRTR2CTSVCTSLMAOBALK | |
| SCHEMBL7242828 | 0.87 | ALDH1A1 (0.40) | HCRTR2MAOBBCHEACHEMAPT | |
| SCHEMBL7250639 | 0.87 | ATM (0.40) | HCRTR2CTSVCTSLMAOBMEN1 | |
| Hydrochloric Acid SCHEMBL7246775 | 0.86 | ATM (0.40) | HCRTR2CTSVCTSLMAOBMEN1 | |
| SCHEMBL7245227 | 0.85 | BCHE (0.47) | HCRTR2BCHEACHECNR1CNR2 | |
| SCHEMBL7250174 | 0.85 | MAOB (0.41) | HCRTR2MAOBMEN1KMT2ABCHE | |
| SCHEMBL7248873 | 0.85 | HCRTR2 (0.42) | HCRTR2CTSVCTSLMAOBMEN1 | |
| SCHEMBL7246577 | 0.84 | HCRTR2 (0.43) | HCRTR2CTSVCTSLMAOBALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045727-A1 | Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups | ADH1A, ADH5, ADH1C | HCRTR2 190/4885CTSV 4705/4885CTSL 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.